t is well established that blood pressure (BP) increases with age. In women, this increase in BP with age is largely because of increases in sympathetic nerve activity and transduction of this sympathetic activity into peripheral vasoconstriction. [1] [2] [3] Some of these conclusions are based from results using intravenous infusions of trimethaphan (TMP).
I
t is well established that blood pressure (BP) increases with age. In women, this increase in BP with age is largely because of increases in sympathetic nerve activity and transduction of this sympathetic activity into peripheral vasoconstriction. [1] [2] [3] Some of these conclusions are based from results using intravenous infusions of trimethaphan (TMP). [4] [5] [6] TMP blocks autonomic neurotransmission by competing for acetylcholine on the postsynaptic nicotinic (NN-cholinergic) receptors in autonomic ganglia. This ganglionic blockade essentially eliminates the influence of both sympathetic and parasympathetic nervous system activity. [4] [5] [6] [7] Although no longer used clinically, this drug has been used as a research tool to assess autonomic support of BP. Our group and others have observed significant reductions in muscle sympathetic nerve activity (MSNA), circulating norepinephrine, heart rate variability (HRV), and arterial BP in healthy young and older individuals with intravenous TMP infusion. [4] [5] [6] [7] [8] As such, individuals will have different BP and heart rate (HR) responses to TMP infusion based on their basal level or ratio of sympathetic and parasympathetic tone.
Because it relates to aging, Seals et al 6 have shown that, in older men, the fall in BP in response to ganglionic blockade is double that of younger men. This group went on to show that younger men had greater parasympathetic support of resting BP, whereas the older men had greater sympathetic support of BP. 6 Consistent with data from older men, our group has shown that the fall in BP with ganglionic blockade in older women is greater than that of younger women 4 ; however, we did not assess the relative contributions of the sympathetic and parasympathetic nervous system. This is important because our group and others have shown that BP regulation differs significantly between men and women. This is especially true when examining autonomic control of BP. Some of the first findings in this area were published by our group, where we show that the relationship between sympathetic nervous system activity and BP increases dramatically in women as they age. 9, 10 Our data also found a loss of β-adrenergic receptor-mediated buffering of BP control in older women after menopause. 11 This is a mechanism uniquely present in women and is not observed in men. The relative contributions of the sympathetic and parasympathetic nervous system are also important because we know that sympathetic activity has a greater rate of rise with age in women than in men, 12 and the ability to buffer sympathetically mediated vasoconstriction through β-adrenergicmediated vasodilation also decreases in women with age. 11, 13 Furthermore, as women age, the transduction of sympathetic activity into increases in BP is increased in women, whereas it decreases in men. 3 Therefore, as women age, they have more sympathetic activity that results in larger changes in BP as compared with men.
In previous work, the average dose of TMP necessary to achieve ganglionic blockade in young women was double of what was given in older women, despite achieving a clear absence of detectable bursts of sympathetic activity by dose 3 to 4 mg/min. 4 In addition, the average dose necessary to achieve autonomic blockade in older women (≈2 mg/min) was substantially lower than previous studies using TMP in young adults (anywhere from 4-8 mg/min). 8, 14, 15 Clinically, individual responses to TMP have been shown to be highly variable, with dosing range from 0.3 to 6 mg/min for the treatment of malignant hypertension. [16] [17] [18] The underlying mechanisms behind large differences in dosing of TMP were unknown previously. The differential contribution of the sympathetic versus parasympathetic nervous system in the dose of TMP required to achieve ganglionic blockade has not been examined.
As such, we sought to understand the contribution of the sympathetic and parasympathetic nervous system to BP control in young and older women.
We further investigated whether differences in the dose of TMP necessary to achieve complete autonomic blockade can provide insight into mechanisms of BP regulation with aging. We hypothesized that the dose of TMP necessary to achieve autonomic blockade would differ between young and older women and would be related to basal levels of sympathetic (MSNA) and parasympathetic (HRV) activity. We further hypothesized relative differences in sympathetic versus parasympathetic support of BP between young and older women would underlie observed changes in BP and HR after ganglionic blockade, where younger women would have greater parasympathetic support of BP than older women. 
Methods

Participants
A total of 42 women (18-76 years of age) participated in the study. Data from 24 of these individuals were published previously. 4, 19 All participants were healthy, nonsmoking, nonobese (body mass index, <28 kg/m 2 ), normotensive, and taking no systemic medications influencing cardiovascular function, with the exception of oral contraceptives (n=19) and menopausal hormonal therapy (n=2). There was an n of 1, 4, 12, and 2 women on generations 1 to 4 of oral contraceptives, respectively. All women were either on or off oral contraceptives for >2 months. Women on oral contraceptives were studied on days 2 to 5 of the placebo phase (>48 hours from the last active pill). All young women (<35 years of age) were studied during the early follicular phase of the menstrual cycle or the placebo phase of oral contraceptive use. None of the participants had a history of diabetes mellitus or prediabetes mellitus in their Mayo Clinic medical record, had a fasting glucose of >126, or reported diabetes mellitus on a screening form.
All young women completed a pregnancy test within 48 hours of the study. All older women were ≥50 years of age and were postmenopausal based on self-report (>12 months from last menstruation).
Participant Monitoring
Studies were performed in the Clinical Research and Trial Unit at the Mayo Clinic where the ambient temperature was controlled between 22°C and 24°C. Participants arrived at the laboratory after an overnight fast and ≥24 hours without caffeine or vigorous exercise. On arrival, participants were asked to rest in a seated position, and BP was taken via sphygmomanometer. Subjects then rested in the supine position during instrumentation. After local anesthesia with 2% lidocaine, a 5-cm 20-gauge arterial catheter was placed in the brachial artery of the nondominant arm, using aseptic technique. Beat-to-beat BP was collected from a pressure transducer connected to the arterial catheter. A 3-lead ECG was used for continuous recordings of HR and to allow for assessment of HRV.
Multiunit MSNA was measured from the right peroneal nerve at the fibular head using insulated tungsten microelectrodes. A muscle sympathetic fascicle was identified when taps on the muscle belly or passive muscle stretch evoked mechanoreceptive impulses, and no afferent neural response was evoked by skin stimuli. The recorded signal was amplified 80 000-fold, band-pass filtered (700-2000 Hz), rectified, and integrated (resistance-capacitance integrator circuit; time constant, 0.1 s) by a nerve traffic analyzer. The signal was amplified, band-pass filtered, rectified, and integrated (662C-4 Nerve Traffic Analysis System; University of Iowa, Iowa City, IA) and then recorded at 250 Hz (WinDaq; DATAQ Instruments, Akron, OH; n=24) or 10 000 Hz (PowerLab; ADInstruments, Colorado Springs, CO; n=18). Sympathetic bursts in the integrated neurogram were identified in the recorded data by a single investigator (S.E.B.) using a semiautomated analysis program that assigns each sympathetic burst to the appropriate cardiac cycle by compensating for latency. 20 In addition to the cardiovascular and neurophysiological criteria included in the automated program, a minimum of a 3:1 signal-to-noise ratio was used for burst confirmation. MSNA is reported as bursts per minute (burst frequency [BF]), bursts per 100 heartbeats (burst incidence [BI]), and total activity (AU).
Drug Administration
Ganglionic blockade was achieved using incremental intravenous infusion of TMP camsylate (Cambridge Laboratories, Wallsend, United Kingdom). Infusions started between 0.5 and 2 mg/min and were increased by 0.5 to 1 mg/min at ≈6-minute intervals up to a maximum of 7 mg/min or until autonomic blockade was established. Subjects were considered blocked if they demonstrated ≥2 of the following criteria: an absence of bursts of sympathetic activity, no change in BP in response to increasing TMP dose, or <5 bpm increase in HR during phase II of the Valsalva maneuver. 21 
Protocol
After the placement of arterial and intravenous catheters, subjects rested quietly in the supine position. Participants remained supine during instrumentation for microneurography. When a good-quality neurogram was established, 10 minutes of quiet resting baseline data were recorded. After the baseline period, ganglionic blockade was then achieved via infusion of TMP (total time: range, 15-45 minutes). Once blockade was determined and a stable HR and BP had been reached, data were recorded during quiet rest. After discontinuation of the TMP infusion and deinstrumentation, subjects remained in the Clinical Research and Trial Unit for ≥2 hours for observation. In cases where we were unable to obtain a quality neurogram (n=4), the participant did not receive TMP, and the study was terminated. One study was terminated early because of nausea and vomiting during the infusion. These data were excluded because the infusion was discontinued before ganglionic blockade.
Data Analysis and Statistics
Steady-state physiological variables (HR, BP, MSNA, and HRV [WinCPRS; Absolute Aliens Oy, Turku, Finland]) were assessed as an average during 5 minutes of baseline and 5 minutes of TMP infusion during ganglionic blockade. Standard short-term recordings (5 minutes) were used to assess time-domain indices of HRV.
22, 23 The root mean square of successive differences between normal heart beats reflects beat-to-beat differences in HR and is generally believed to reflect parasympathetic activity. 24 The percentage of adjacent normal-to-normal intervals that differ by >50 ms is also believed to be a marker of parasympathetic activity. 25 As such, these indices were used as our indices of parasympathetic activity. Differences between data collected during baseline and ganglionic blockade were taken as the measure of autonomic support. 6 Data were analyzed statistically using commercially available software (Sigma Plot 12 [San Jose, CA]; IBM SPSS Statistics, version 22 [Chicago, IL]). Baseline group differences were assessed using independent sample t tests, and data are expressed as mean±SEM. Repeated measures ANOVA was used to assess changes in BP and other hemodynamic parameters with ganglionic blockade by group. To measure whether there was a relationship of TMP dose necessary to achieve ganglionic blockade and hemodynamic variables, regression analysis was performed, and Pearson-Spearman ρ correlation coefficients were calculated. Spearman ρ was used because TMP dose is a noncontinuous variable. Regression analysis was performed on pooled data (young and older women) unless otherwise specified. The α-level was set at 0.05.
Results
Baseline Differences and Effect of Ganglionic Blockade
A total of 18 older women (59.8±2 years of age) and 24 younger women (25.8±1 years of age) participated in this study. Weight and body mass index did not differ between groups; however, the younger women were taller than the older women (Table 1; P<0.05). MSNA was higher in the older women as compared with the younger women ( Table 1 ; P<0.05), whereas systolic BP, mean BP, diastolic BP, and resting HR were not significantly different between age groups ( Table 1) . Measures of HRV (root mean square of the successive differences in R-R interval, standard deviation of the R-R interval, and percentage of adjacent normal-to-normal intervals that differ by >50 ms) were lower in the older women compared with the younger women (Table 1 ; all P<0.05). Similar to our previous work, the average TMP dose necessary to achieve complete ganglionic blockade was greater in younger women (4.3±0.3 mg/min) when compared with older women (1.9±0.2 mg/min; P<0.001). Although the average dose of TMP was lower in the older women, they had a larger reduction in mean arterial pressure, HRV was significantly reduced, and sympathetic nerve activity was eliminated during steady-state infusion (Table 2 ). When the Valsalva maneuver was conducted during the final steady-state dose of TMP infusion, there was a significant reduction in mean arterial pressure (MAP; ΔMAP with Valsalva: young, −21±9; older, −18±9 mm Hg) without a reflex increase in HR (ΔHR with Valsalva: young, 2.4±4.0; older, 3.5±6 bpm), suggesting that we achieved ganglionic blockade. As expected, there was a significant increase in HR and decrease in BP in both groups during blockade of the autonomic ganglia. The increase in HR during ganglionic blockade was greater in younger women when compared with older women, resulting in a smaller fall in BP during ganglionic blockade in the younger women (P<0.001; Table 2 ). Measures of HRV decreased significantly in both groups during ganglionic blockade (with the exception of percentage of adjacent normal-to-normal intervals that differ by >50 ms in the older women; Table 2 ; all P<0.05).
Relationship Between TMP Doses Required for Autonomic Blockade and Autonomic Indices
The dose of TMP necessary to achieve complete ganglionic blockade was related to baseline HRV (R-R interval: r s =0.079, P=0.617; SD R-R interval: r s =0.581; root mean square of the successive differences in R-R interval: r=0.453; percentage of adjacent normal-to-normal intervals that differ by >50 ms: r=0.592, P<0.001 for all but R-R interval; Figure 1 ) where greater variability in resting HR was related to a higher dose of TMP necessary to achieve ganglionic blockade. Baseline MSNA (BI and BF) was negatively correlated to TMP dose when looking at young and older women together; however, when considering the age groups separately, there was no relationship in the older women and a positive relationship between MSNA and TMP dose in the young women 
Mechanistic Differences in Autonomic Cardiovascular Control Between Young and Older Women Underlie Observed Changes in BP and HR
The change in mean arterial pressure with autonomic blockade was significantly related to the dose of TMP, where women requiring the largest dose of TMP had the smallest change in mean arterial pressure (r s =0.787, P<0.001; Figure 3 ). The Values are mean±SE. AU indicates total activity; BI, burst incidence; BMI, body mass index; BP, blood pressure; HR, heart rate; MHT, menopausal hormone therapy; MSNA, muscle sympathetic nerve activity; OCP, oral contraceptives; pNN50, %R-R interval differences >50 ms; and RMSSD, root mean square of the successive differences in R-R interval.
Age group differences: *P<0.001, †P<0.05, ‡P<0.01.
change in HR with autonomic blockade was related to TMP dose, such that women who required the largest doses of TMP to achieve ganglionic blockade had the largest changes in HR (r s =0.631, P<0.001; Figure 3 ).
Discussion
The main novel findings from the present study are 3-fold: (1) the dose of TMP required to achieve ganglionic blockade in older women was nearly half of that required to achieve ganglionic blockade in young women, (2) sympathetic support of BP (relationship between MSNA and fall in BP) was the most evident in women requiring the lowest dose of TMP (older women), (3) parasympathetic support of BP (relationship between HRV and rise in HR) was the most evident in women requiring the highest dose of TMP (younger women). During TMP infusion, both sympathetic activity and parasympathetic activity are blocked at the autonomic ganglia. The combination of the two will result in a fall in MSNA and total peripheral resistance (sympathetic), as well as a reduction in HRV and an increase in HR (parasympathetic). The combination of the two would thus be expected to achieve a relatively small change in systemic arterial pressure because of the compensation of any fall in total peripheral resistance by the increase in HR and cardiac output. However, BP is significantly reduced in both younger and older women (and men 6 ) during TMP infusion. Because TMP in the doses we used eliminates both sympathetic and parasympathetic tone, populations of individuals (eg, aging) will have different BP responses to TMP infusion based on the basal level or ratio of sympathetic to parasympathetic tone. Our data show that the young women studied have a larger parasympathetic contribution (higher HRV) at rest when compared with older women. During TMP infusion, these young women thus exhibit a greater increase in HR and, therefore, cardiac output compared with the older women. In contrast, older women have greater sympathetic activity (higher MSNA) and lower parasympathetic activity (HRV) at rest. With this, very little change in HR is observed in response to TMP, despite a significant fall in MSNA and peripheral vascular tone in older women. Our data are in agreement with those seen in men, where older men had lower baseline HRV and the change in HR with TMP was positively associated with baseline HRV. 6 Data from the present investigation also suggest that in the basal state, high sympathetic tone in older women is relatively unopposed by parasympathetic tone and plays a more dominant role in baseline BP.
Blockade of the sympathetic nervous system is achieved early in the dosing scheme for TMP (MSNA and baroreflex function are effectively lost in the early doses [2-3 mg/min]-no apparent sympathetic bursts of activity) 8, 19, 26 and yet a dose ≤7 mg/min was necessary in some younger women to achieve blockade (ie, a lack of an HR response to the Valsalva maneuver). With this observation, we began to speculate whether blocking the parasympathetic nervous system requires a higher dosage of TMP. Consistent with this idea, anatomic placement of the ganglia differs between the sympathetic (paraspinal) and parasympathetic (on the organ) nervous system. Therefore, perhaps these differences in placement affect the amount of drug (dose) necessary to effectively achieve effective blockade. Consistent with this, we did not observe a relationship between baseline MSNA and TMP dose. Conversely, a strong relationship between HRV and TMP dose was observed, indicating a strong parasympathetic contribution to the TMP dose required to achieve autonomic blockade. A similar dosing strategy to ours was used by Seals et al 6 ; however, the final doses were not included in the published article, so it is unclear whether the age-related dosing differences we saw in women also translate into men. Diedrich et al also used an incremental dosing approach. They were able to differentiate between sympathetically dependent hypertension (multiple system atrophy) and nonsympathetically dependent hypertension (pure autonomic failure) using the relationship between BP and incremental TMP dosing. Patients with sympathetically dependent hypertension generally had dramatic and immediate drops in BP with low doses of TMP (<2 mg/min), whereas the patients with sympathetically independent hypertension were all able to tolerate large doses of TMP (≤8 mg/min). These data further highlight the importance physiology plays in dictating the dose of TMP required to achieve ganglionic blockade.
Considerations
There are several important limitations to consider. First, large changes in BP, like those experienced during ganglionic blockade, are a trigger for the release of vasopressin. Potential differences in the vasopressin response between young and older women were not investigated in this study but could potentially influence the hemodynamic response to ganglionic blockade. 7 Second, we are unable to address the impact of hormonal contraceptives on the responses in young women because 19 of 24 women were on hormonal contraceptives. However, our group has demonstrated that basal MSNA does not differ between normally cycling women and those using oral hormonal contraceptives, despite an ≈5-mm Hg increase in BP in women on oral contraceptives. 27 Given around 80% of women are exposed to oral contraceptives at some point in their lifetime 28, 29 and that the hemodynamic data were qualitatively similar (ΔMAP with TMP, −10±2 versus −9±2 mm Hg; ΔHR with TMP, 22±3 versus 26±4 bpm oral contraceptives vs naturally cycling), we feel the Change in mean arterial pressure (MAP) and heart rate in response to ganglionic blockade as a function of trimethaphan dose required to achieve ganglionic blockade in young and older women. A, The dose of trimethaphan required to achieve ganglionic blockade is significantly related to the change in MAP (r s =0.787, P<0.001). B, The dose of trimethaphan required to achieve ganglionic blockade is significantly related to the change in heart rate with ganglionic blockade (r s =0.631, P<0.001). present group is representative of the current population of young women. It is also important to acknowledge that 2 older women were on menopausal hormone therapy; however, their data were undistinguishable from the rest of the older women in their baseline measures and response to ganglionic blockade. Although these data suggest our conclusions are not affected by the use of hormonal contraceptives or hormone replacement therapy, future work in this area is warranted. Finally, TMP is a rapidly acting N N -cholinergic antagonist that achieves pharmacological ganglionic blockade by inhibiting cholinergic transmission at the nicotinic receptors of the sympathetic ganglia. It was used in the management of hypertensive cardiovascular disease, in addition to emergency control of BP in patients with acute dissecting aortic aneurysm 30, 31 and to reduce bleeding during surgery. 16, 32 The current therapeutic uses of TMP are limited because of the competition from newer drugs that are more selective in their actions and effects produced. With this, TMP is no longer produced, and there are only small quantities existing for physiology research.
Perspectives
Although TMP is no longer used, these data illustrate the large differences between older and younger individuals in respect to compensatory hemodynamics. Other currently clinically used antihypertensive therapies also reduce sympathetic outflow or tone (eg, α-adrenergic blockers and centrally acting agents) and, therefore, total peripheral resistance. Although these compounds operate through different mechanisms than TMP, they all essentially reduce total peripheral resistance, and the reduced parasympathetic tone in this population means that they have a reduced capacity to buffer acute drops in BP and may lead to the higher risk of adverse events seen in this population. Older individuals are more likely to require antihypertensive therapy at lower dosages, and their risk of adverse effects is higher in older than in younger individuals (eg, hypotension and syncope). This may be explained, in part, by the inability to fully compensate BP changes with parasympathetic withdrawal as in younger individuals. In summary, these data highlight the importance of increased sympathetic tone along with the loss of parasympathetic compensation on the increase in BP with age in women. Furthermore, the inability to fully compensate BP changes with the withdrawal of parasympathetic tone in older women has important implications for dosing and risk of adverse events with antihypertensive therapies.
